Retatrutide Dose Escalation for Adult Obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with Comorbidities)
Retatrutide has been studied in adult obesity trials using once-weekly subcutaneous dosing with scheduled stepwise escalation every 4 weeks rather than individualized “micro-dosing.” [1] No obesity guideline recommends a specific “micro-dosing” titration protocol for retatrutide. [1]
Medication Selection Algorithm
Retatrutide is administered as a once-weekly subcutaneous injection for obesity with weight-related indications in clinical trial protocols. [1] Dose escalation is implemented only in the absence of trial-defined contraindications and clinically significant intolerance to prior doses. [1]
Key Evidence Supporting This Recommendation
In the phase 2 obesity development program, participants were titrated step-wise after initiation at 2 mg once weekly with increases occurring every 4 weeks until reaching the target maintenance dose. [1] For targets of 9 mg, dose steps were described as 2 mg, 4 mg, and 6 mg. [1] For targets of 12 mg, dose steps were described as 2 mg, 4 mg, 6 mg, and 9 mg. [1]
Monotherapy Versus Combination Therapy
Retatrutide has been studied as part of obesity management with background lifestyle counseling rather than as a mandated combination pharmacotherapy regimen. [2] No obesity titration protocol has been established that depends on combination with another anti-obesity medication. [1]
Treatment Initiation Thresholds
Initiation in clinical development has used adult populations with obesity or overweight with weight-related comorbidities. [2] Weekly dose escalation has been structured as a protocolized schedule rather than symptom-triggered “micro-dosing.” [1]
Recommended Titration Protocol (Once-Weekly Subcutaneous Step-Up)
The following step-up schedule reflects the described phase 2/phase 3 style retatrutide initiation and escalation framework used in the clinical development program: [1]
- Start: retatrutide 2 mg subcutaneously once weekly for the initial 4-week interval. [1]
- Week 5: increase to retatrutide 4 mg subcutaneously once weekly. [1]
- Week 9: increase to retatrutide 6 mg subcutaneously once weekly. [1]
- Week 13: increase to retatrutide 9 mg subcutaneously once weekly (when targeting 9 mg maintenance). [1]
- Week 13: increase to retatrutide 9 mg subcutaneously once weekly (when targeting 12 mg maintenance). [1]
- Week 17: increase to retatrutide 12 mg subcutaneously once weekly (when targeting 12 mg maintenance). [1]
Important Clarifications and Nuances
“Micro-dosing” schedules that split the weekly dose or introduce non-protocolized sub-2 mg increments have not been established in the obesity development dosing framework described above. [1] Dose increases occur at 4-week intervals in the described step-wise titration pathway. [1] If intolerance develops at any step, escalation is typically deferred or stopped according to clinical trial safety management rather than continued with nonstandard micro-dosing. [1]
Common Pitfalls to Avoid
Escalation earlier than the 4-week interval used in the studied step-up framework can increase gastrointestinal intolerance risk. [1] Using non-protocolized micro-dosing regimens without trial evidence can create inconsistent exposure relative to studied dosing arms. [1] Continuing escalation in the setting of severe or persistent adverse effects conflicts with the trial-based approach to dose management used during development. [1]
Targets or Goals of Therapy
The studied maintenance targets for obesity dosing include 9 mg and 12 mg once weekly following the described escalation steps. [1] Achievement of maintenance dosing is protocol dependent on tolerability and scheduled stepwise titration. [1]